$IRON
Disc Medicine, Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022008015 Filed on May 06, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.673M $4.700M
YoY Change -0.57%
% of Gross Profit
Research & Development $9.804M $11.79M
YoY Change -16.82% 43.43%
% of Gross Profit
Depreciation & Amortization $0.00 $65.00K
YoY Change -100.0% -15.58%
% of Gross Profit
Operating Expenses $15.18M $16.49M
YoY Change -7.96% 71.22%
Operating Profit -$15.18M -$16.49M
YoY Change -7.96% 71.22%
Interest Expense $66.00K $1.848M
YoY Change -96.43% 1107.84%
% of Operating Profit
Other Income/Expense, Net $3.000K $700.0K
YoY Change -99.57%
Pretax Income -$15.23M -$19.05M
YoY Change -20.05%
Income Tax
% Of Pretax Income
Net Earnings -$15.23M -$19.05M
YoY Change -20.04% 95.44%
Net Earnings / Revenue
Basic Earnings Per Share -$10.67
Diluted Earnings Per Share -$352.5K -$594.8K
COMMON SHARES
Basic Shares Outstanding 43.21M
Diluted Shares Outstanding 923.8K

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $119.1M $185.0M
YoY Change -35.64%
Cash & Equivalents $119.1M $185.0M
Short-Term Investments
Other Short-Term Assets $5.004M $3.600M
YoY Change 39.0%
Inventory
Prepaid Expenses $4.681M $3.619M
Receivables
Other Receivables
Total Short-Term Assets $124.1M $188.6M
YoY Change -34.22%
LONG-TERM ASSETS
Property, Plant & Equipment $229.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $217.0K $225.0K
YoY Change -3.56%
Total Long-Term Assets $217.0K $777.0K
YoY Change -72.07%
TOTAL ASSETS
Total Short-Term Assets $124.1M $188.6M
Total Long-Term Assets $217.0K $777.0K
Total Assets $124.3M $189.4M
YoY Change -34.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.110M $3.562M
YoY Change 43.46%
Accrued Expenses $3.405M $5.200M
YoY Change -34.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.159M $5.000M
YoY Change -16.82%
Total Short-Term Liabilities $12.67M $13.78M
YoY Change -8.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $4.100M
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $300.0K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $4.400M
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.67M $13.78M
Total Long-Term Liabilities $0.00 $4.400M
Total Liabilities $12.67M $18.22M
YoY Change -30.44%
SHAREHOLDERS EQUITY
Retained Earnings -$199.9M -$131.9M
YoY Change 51.61%
Common Stock $4.000K $4.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $111.6M $171.2M
YoY Change
Total Liabilities & Shareholders Equity $124.3M $189.4M
YoY Change -34.37%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$15.23M -$19.05M
YoY Change -20.04% 95.44%
Depreciation, Depletion And Amortization $0.00 $65.00K
YoY Change -100.0% -15.58%
Cash From Operating Activities -$16.34M -$15.01M
YoY Change 8.87% 51.88%
INVESTING ACTIVITIES
Capital Expenditures $100.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$100.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.225M 195.5M
YoY Change -100.63% 872.88%
NET CHANGE
Cash From Operating Activities -16.34M -15.01M
Cash From Investing Activities -100.0K
Cash From Financing Activities -1.225M 195.5M
Net Change In Cash -17.56M 180.5M
YoY Change -109.73% 1667.19%
FREE CASH FLOW
Cash From Operating Activities -$16.34M -$15.01M
Capital Expenditures $100.0K
Free Cash Flow -$16.44M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Gemini Therapeutics, Inc. /DE
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001816736
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39438
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1612845
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
297 Boston Post Road #248
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Wayland
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01778
CY2022Q1 dei City Area Code
CityAreaCode
617
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
401-4400
CY2022Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
GMTX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43227159
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
119064000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
136627000
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
323000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
223000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4681000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3250000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
124068000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
140100000
CY2022Q1 gmtx Non Current Restricted Cash2
NonCurrentRestrictedCash2
0
CY2021Q4 gmtx Non Current Restricted Cash2
NonCurrentRestrictedCash2
100000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
217000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
237000
CY2022Q1 us-gaap Assets
Assets
124285000
CY2021Q4 us-gaap Assets
Assets
140437000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5110000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2950000
CY2022Q1 gmtx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
3405000
CY2021Q4 gmtx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6884000
CY2022Q1 us-gaap Loans Payable Current
LoansPayableCurrent
4159000
CY2021Q4 us-gaap Loans Payable Current
LoansPayableCurrent
5000000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
12674000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14834000
CY2022Q1 us-gaap Other Liabilities
OtherLiabilities
0
CY2021Q4 us-gaap Other Liabilities
OtherLiabilities
358000
CY2022Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
0
CY2021Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
404000
CY2022Q1 us-gaap Liabilities
Liabilities
12674000
CY2021Q4 us-gaap Liabilities
Liabilities
15596000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43227159
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43227159
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43208159
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43208159
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
311528000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
309527000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199921000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-184690000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
111611000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
124841000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124285000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
140437000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9804000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11786000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5373000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4704000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
15177000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
16490000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15177000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16490000
CY2022Q1 us-gaap Interest Expense
InterestExpense
66000
CY2021Q1 us-gaap Interest Expense
InterestExpense
1848000
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
9000
CY2021Q1 us-gaap Interest Income Other
InterestIncomeOther
1000
CY2022Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0
CY2021Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
711000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15231000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-19048000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43212803
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32027161
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-21861000
CY2021Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
195882000
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
14515000
CY2021Q1 gmtx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
76000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2021Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1593000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-19048000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
171161000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2022Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1976000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15231000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
111611000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-15231000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-19048000
CY2022Q1 us-gaap Depreciation
Depreciation
0
CY2021Q1 us-gaap Depreciation
Depreciation
65000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1976000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1593000
CY2022Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
36000
CY2021Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
188000
CY2021Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
711000
CY2022Q1 gmtx Accretion Of Discount On Convertible Notes
AccretionOfDiscountOnConvertibleNotes
0
CY2021Q1 gmtx Accretion Of Discount On Convertible Notes
AccretionOfDiscountOnConvertibleNotes
1600000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1430000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3057000
CY2022Q1 gmtx Increase Decrease In Deferred Offering Costs
IncreaseDecreaseInDeferredOfferingCosts
0
CY2021Q1 gmtx Increase Decrease In Deferred Offering Costs
IncreaseDecreaseInDeferredOfferingCosts
-1341000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-20000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
225000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2159000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2173000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3868000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-348000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16338000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15007000
CY2021Q1 gmtx Proceeds From Business Combination Net
ProceedsFromBusinessCombinationNet
196319000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
CY2022Q1 gmtx Principal Payments On Term Loan
PrincipalPaymentsOnTermLoan
1250000
CY2021Q1 gmtx Principal Payments On Term Loan
PrincipalPaymentsOnTermLoan
833000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1225000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
195490000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17563000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
180483000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136950000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4826000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119387000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
185309000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
47000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
60000
CY2022Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2021Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
14515000
CY2021Q1 gmtx Exercise Of Warrants
ExerciseOfWarrants
76000
CY2021Q1 gmtx Unpaid Issuance Costs In Accounts Payable And Accrued Expenses And Other Current Liabilities
UnpaidIssuanceCostsInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
437000
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of the business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Gemini Therapeutics, Inc. (the “Company” or “Gemini”) is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The Company was founded on March 3, 2015.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Unless the context otherwise requires, references in these notes to “Gemini”, “the Company”, “we”, “us” and “our” and any related terms are intended to mean Gemini Therapeutics, Inc. and its consolidated subsidiary following the Business Combination (as defined below).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has devoted substantially all its efforts and financial resources to organizing and staffing the Company, business planning, raising capital, discovering product candidates and securing related intellectual property rights and conducting research and development activities for its product candidates. In January 2022, the Company discontinued both of its Phase 2a clinical trials for GEM103. The Company's other product candidate, GEM307, is in the preclinical stage of development.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In February 2022, the Company announced a corporate restructuring and that it initiated a process to evaluate strategic alternatives. The Company expects to devote substantial time and resources to exploring strategic alternatives that its board of directors believes will maximize shareholder value. Despite devoting significant efforts to identify and evaluate potential strategic alternatives, there can be no assurance that this strategic review process will result in the Company pursuing any transaction or that any transaction, if pursued, will be completed on attractive terms or at all. The Company has not set a timetable for completion of this strategic review process, and its board of directors has not approved a definitive course of action. Additionally, there can be no assurances that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated or lead to increased stockholder value or that the Company will make any additional cash distributions to its stockholders.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On February 5, 2021 (the “Closing Date”), FS Development Corporation, a Delaware corporation (“FSDC”), consummated the previously announced business combination (the “Business Combination”) pursuant to the terms of the Agreement and Plan of Merger, dated as of October 15, 2020 (as amended, supplemented or otherwise modified from time to time, the “Merger Agreement”), by and among Gemini Therapeutics, Inc., a Delaware corporation (“Old Gemini”), Shareholder Representative Services LLC, a Colorado limited liability company solely in its capacity as the representative, agent and attorney-in-fact of the Company Securityholders (the “Stockholders’ Representative”), FSDC and FSG Merger Sub Inc., a Delaware corporation (“Merger Sub”).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">FSDC was incorporated in Delaware on June 25, 2020 and was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On the day prior to the Closing Date, Old Gemini changed its name to “Gemini Therapeutics Sub, Inc.” Pursuant to the Merger Agreement, on the Closing Date, (i) FSDC changed its name to “Gemini Therapeutics, Inc.” and (ii) Old Gemini merged with and into Merger Sub (the “Merger”), with Old Gemini as the surviving company in the Merger and, after giving effect to such Merger, Old Gemini becoming a wholly-owned subsidiary of Gemini. Upon the closing of the Business Combination, and pursuant to the terms of the Merger Agreement, the existing shareholders of Old Gemini exchanged their interests for shares of common stock of Gemini.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Business Combination, certain investors purchased an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">95.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company’s Common Stock in a private placement of public equity (the “PIPE Financing”). Together with FSDC’s cash resources and funding of the PIPE Financing, the Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">195.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">For additional information on the Business Combination, please refer to Note 2, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business Combination</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, to these condensed consolidated financial statements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing, compliance with government regulations and the impact of the ongoing and evolving novel coronavirus disease (“COVID-19”) pandemic. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company’s product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and is dependent upon the services of its employees, consultants, third-party contract research organizations and other third-party organizations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Business Combination, the Company primarily financed its operations through the sale of convertible preferred stock, borrowings under convertible promissory notes and borrowings under loan agreements. The Company believes that its </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">119.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> of cash and cash equivalents as of March 31, 2022 will enable it to fund its planned operations for at least twelve months from the issuance date of these condensed consolidated financial statements, though the Company may raise additional capital through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Management’s expectations with respect to its ability to fund current planned operations is based on estimates that are subject to risks and uncertainties. Its operating plan may change as a result of many factors currently unknown to management, and there can be no assurance that the current operating plan will be achieved in the time frame anticipated by the Company, and it may need to seek additional funds sooner than anticipated. Furthermore, the operating plan could materially change depending on the outcome of our ongoing strategic alternative review process, including to the extent we identify and enter into any potential strategic transaction. If adequate funds are not available to the Company on a timely basis, on acceptable terms or at all, management may be required to delay, limit, reduce or terminate certain of its research, product development or future commercialization efforts, obtain funds through arrangements with collaborators on terms unfavorable to the Company, or pursue merger or acquisition strategies, all of which could adversely affect the holdings or the rights of its stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impact of the COVID-19 Pandemic</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The ongoing COVID-19 pandemic and the increased prevalence of variants of the virus, and government measures taken in response, have had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. The ongoing COVID-19 pandemic and related impacts have resulted in and will likely continue to result in significant disruptions to the global economy and capital markets around the world. The Company cannot predict the future progression or full impact of the outbreak and its effects on the Company’s business and operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has not incurred impairment losses in the carrying values of its assets as a result of the ongoing COVID-19 pandemic, and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these condensed consolidated financial statements. Although the COVID-19 pandemic did not have a significant impact on the Company’s condensed consolidated financial results in the first quarter of 2022, the full extent to which the ongoing COVID-19 pandemic may impact the Company’s business, results of operations, financial condition and cash flows will depend on future developments that are highly uncertain, and the estimates of the impact on the Company’s business may change based on new information that may emerge concerning COVID-19, including the duration of the pandemic, any potential subsequent waves or strains of COVID-19 infection, the effectiveness, distribution and acceptance of COVID-19 vaccines and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.</span></p>
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
119100000
CY2021Q1 gmtx Net Proceeds From Business Combination
NetProceedsFromBusinessCombination
195900000
CY2021Q1 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
21000000.0
CY2021Q1 gmtx Equity Issuance Costs And Other Costs
EquityIssuanceCostsAndOtherCosts
-20960000
CY2021Q1 us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
195882000
CY2021Q1 gmtx Number Of Shares Issued Due To Business Combination And Private Investment In Public Equity
NumberOfSharesIssuedDueToBusinessCombinationAndPrivateInvestmentInPublicEquity
25041150
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42998664
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates contained within these financial statements include, but are not limited to, the accruals of research and development expenses, share-based awards utilized for stock-based compensation purposes and, prior to the Business Combination, the estimated fair value of the Company’s common stock and warrant liability. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ materially from those estimates or assumptions.</span></p>
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
300000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
300000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
119064000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
136627000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
323000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
323000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119387000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136950000
CY2022Q1 gmtx Accrued Payroll And Benefits
AccruedPayrollAndBenefits
1756000
CY2021Q4 gmtx Accrued Payroll And Benefits
AccruedPayrollAndBenefits
2603000
CY2022Q1 gmtx Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
695000
CY2021Q4 gmtx Accrued Research And Development Expense
AccruedResearchAndDevelopmentExpense
4031000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
565000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
233000
CY2022Q1 gmtx End Of Term Charge For Term Loan
EndOfTermChargeForTermLoan
376000
CY2021Q4 gmtx End Of Term Charge For Term Loan
EndOfTermChargeForTermLoan
0
CY2022Q1 gmtx Accrued Interest
AccruedInterest
13000
CY2021Q4 gmtx Accrued Interest
AccruedInterest
17000
CY2022Q1 gmtx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
3405000
CY2021Q4 gmtx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6884000
CY2021Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
11
CY2021Q4 gmtx Percentage Of Workforce
PercentageOfWorkforce
0.26
CY2021Q4 us-gaap Severance Costs1
SeveranceCosts1
1400000
CY2022Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
24
CY2022Q1 gmtx Percentage Of Workforce
PercentageOfWorkforce
0.80
CY2022Q1 us-gaap Restructuring Costs
RestructuringCosts
1700000
CY2022Q1 gmtx Unpaid Severance Costs
UnpaidSeveranceCosts
1500000
CY2022Q1 us-gaap Severance Costs1
SeveranceCosts1
1700000
CY2021 gmtx Unpaid Severance Costs
UnpaidSeveranceCosts
900000
CY2020Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
14000000.0
CY2020Q3 gmtx Accrued Simple Interest
AccruedSimpleInterest
0.08
CY2021Q1 us-gaap Other Expenses
OtherExpenses
700000
CY2022Q1 us-gaap Interest Expense Customer Deposits
InterestExpenseCustomerDeposits
0
CY2021Q1 us-gaap Interest Expense Customer Deposits
InterestExpenseCustomerDeposits
1700000
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 gmtx Preferred Stock Shares Outstanding1
PreferredStockSharesOutstanding1
0
CY2022Q1 gmtx Preferred Stock Shares Issued1
PreferredStockSharesIssued1
0
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1728326
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1976000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1593000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15231000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-19048000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43212803
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32027161
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6752133
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5602935
CY2022Q1 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
0
CY2021Q1 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
100000

Files In Submission

Name View Source Status
0000950170-22-008015-index-headers.html Edgar Link pending
0000950170-22-008015-index.html Edgar Link pending
0000950170-22-008015.txt Edgar Link pending
0000950170-22-008015-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gmtx-20220331.htm Edgar Link pending
gmtx-20220331.xsd Edgar Link pending
gmtx-20220331_cal.xml Edgar Link unprocessable
gmtx-20220331_def.xml Edgar Link unprocessable
gmtx-20220331_htm.xml Edgar Link completed
gmtx-20220331_lab.xml Edgar Link unprocessable
gmtx-20220331_pre.xml Edgar Link unprocessable
gmtx-ex10_1.htm Edgar Link pending
gmtx-ex31_1.htm Edgar Link pending
gmtx-ex31_2.htm Edgar Link pending
gmtx-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending